Korean J Med.  2018 Oct;93(5):439-446. 10.3904/kjm.2018.93.5.439.

Antimicrobial Therapy for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria

• Wi YM
• Kang CI

• KMID: 2446985
• DOI: http://doi.org/10.3904/kjm.2018.93.5.439

Abstract

Carbapenem-resistance emerging in Gram-negative pathogens, such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, has become a major human health problem globally. The therapeutic options available for carbapenem-resistant pathogens are very limited. Antibiotics such as colistin, tigecycline, fosfomycin, and aminoglycosides are often the only ones that can be used to treat carbapenem-resistant pathogens. Carbapenem may still be an option in certain circumstances. The administration of combination therapy for carbapenem-resistant pathogens is controversial. This review presents the current knowledge of available antimicrobial therapeutic options for infections due to carbapenem-resistant pathogens in Korea.

Keyword

Gram-negative bacteria; Carbapenem; Drug resistance; Treatment outcome

MeSH Terms

Acinetobacter baumannii
Aminoglycosides
Anti-Bacterial Agents
Colistin
Drug Resistance
Fosfomycin
Gram-Negative Bacteria*
Humans
Klebsiella pneumoniae
Korea
Pseudomonas aeruginosa
Treatment Outcome
Aminoglycosides
Anti-Bacterial Agents
Colistin
Fosfomycin